

# Retail Equity Research

## Biocon Limited

Sector: Pharmaceuticals

**ACCUMULATE**
2<sup>nd</sup> January, 2026

Key Changes		Target	▲	Rating	▲	Earnings	▲	Target	Rs. 439
Stock Type	Bloomberg Code	Sensex		NSE Code		BSE Code		Time Frame	
Mid Cap	BIOS:IN	85,189		BIOCON		532523		12 Months	

Data as of: 01-01-2026, 18:00 hrs

Company Data			
Market Cap (Rs.cr)		51,841	
52 Week High — Low (Rs.)		425 - 291	
Enterprise Value (Rs. cr)		69,271	
Outstanding Shares (cr)		133.7	
Free Float (%)		44.8	
Dividend Yield (%)		0.1	
6m average volume (cr)		0.4	
Beta		1.3	
Face value (Rs. )		5.0	

Shareholding (%)	Q4FY25	Q1FY26	Q2FY26
Promoters	60.6	54.5	54.5
FII's	5.7	6.0	6.6
MFs/Institutions	15.7	22.8	22.1
Public	14.8	13.7	13.8
Others	3.2	3.0	3.0
Total	100.0	100.0	100.0
Promoter Pledge	Nil	Nil	Nil

Price Performance	3 Month	6 Month	1 Year
Absolute Return	13.7%	5.2%	6.8%
Absolute Sensex	5.2%	2.4%	8.6%
Relative Return	8.5%	2.8%	-1.7%

\*over or under performance to benchmark index



Y.E March (Rs.cr)	FY25A	FY26E	FY27E
Sales	15,262	17,938	21,104
Growth (%)	5.9	17.5	17.6
EBITDA	3,166	3,659	4,704
EBITDA Margin (%)	20.7	20.4	22.3
PAT Adjusted	-140	640	1,364
Growth (%)	-191.6	557.1	113.1
Adjusted EPS	-1.2	4.8	10.2
Growth (%)	-192.3	500.0	112.5
P/E	n.m.	85.6	40.2
P/B	1.9	2.5	2.3
EV/EBITDA	20.5	21.3	16.5
ROE (%)	6.6	4.0	6.8
D/E	0.8	0.7	0.7

### Robust Pipeline to Drive Future Growth

Biocon Ltd is a biopharmaceutical company that develops therapies for chronic diseases such as autoimmune, cancer and diabetes. The company has developed and introduced novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogues.

- Consolidated revenue in Q2FY26 increased 19.6% YoY to Rs. 4,296cr aided by growth in biosimilars, generics and CRDMO.
- Adjusted EBITDA increased 21.9% YoY to Rs. 835cr and margin grew 40bps YoY to 19.4% driven by strong topline expansion.
- Revenue from biosimilars grew 24.7% YoY to Rs. 2,721cr, fuelled by market share gains and new product launches.
- Biocon launched Kirsty™, the first and only FDA approved interchangeable biosimilar to NovoLog® (insulin aspart), strengthening its diabetes portfolio.
- Biocon has proposed to acquire the remaining minority investors stake in Biocon Biologics (23.3%), making Biocon Biologics a wholly owned subsidiary of the company, using a combination of equity swaps and QIP to fund the transaction.

### Outlook & valuation

Biocon has strengthened its financial position by settling structured debt obligations resulting in a notable reduction in interest costs that is expected to support margins going forward. The company has also simplified its corporate structure, enhancing operational efficiency and governance transparency. Its strong biosimilars portfolio, led by insulin and recently launched oncology products, is poised to drive growth, while the generic business is expected to gain momentum in 2HFY26 through new product launches, capitalizing on the Ozempic opportunity and global expansion. Although margins remain impacted by new facilities and the lower-margin formulation business, interest cost savings and operating leverage from biosimilars should aid recovery over time. Hence, we upgrade our stance to **ACCUMULATE** from **Reduce** with a target price of Rs. 439, based on 43x FY27E adjusted EPS.


### Quarterly Financials Consolidated

Rs.cr	Q2FY26	Q2FY25	YoY (%)	Q1FY26	QoQ (%)	H1FY26	H1FY25	YoY (%)
Sales	4,296	3,590	19.6	3,942	9.0	8,237	7,023	17.3
Adj EBITDA	835	685	21.9	766	9.0	1,601	1,306	22.6
Margin (%)	19.4	19.1	36bps	19.4	1bps	19.4	18.6	84bps
EBIT	455	298	52.8	391	16.5	846	1,648	-48.7
PBT	171	98	74.1	97	76.8	268	1,244	-78.4
Rep. PAT	133	27	390.0	89	48.9	222	889	-75.0
Adj PAT	96	-42	328.6	49	98.4	145	-472	130.7
Adj. EPS (Rs)	0.72	-0.35	305.7	0.4	98.4	1.1	-3.9	128.2


## Key concall highlights

- In Q2FY26, biosimilars accounted for 61% of the total revenue, CRDMO 21% and generics 18%.
- Biocon's first oral solid dosage (OSD) manufacturing facility was inaugurated in the US, marking a significant step towards expanding the vertically integrated portfolio for patients in the region.
- During the quarter, the company received 13 new approvals and successfully launched 19 products across major markets.
- It achieved a milestone with its first global phase III clinical trial from a US-based biotech company, with patients recruited across India and US clinical sites. Syngene also broadened its clinical trials footprint to Australia, New Zealand, the UK, Sri Lanka and Eastern Europe.
- The management expects biosimilars R&D spend to continue in the 7-9% range of revenue for the full year.
- It expects the R&D spend for generics to remain in 8-10% range of revenue, with gross margin expected to improve from the current mid-40s levels.


### Revenue




### R&D Spend



### Adj EBITDA



### PAT



### Change in Estimates

Year / Rs cr	Old estimates		New estimates		Change (%)	
	FY26E	FY27E	FY26E	FY27E	FY26E	FY27E
Revenue	17,534	20,629	17,938	21,104	2.3	2.3
EBITDA	3,739	4,866	3,659	4,704	-2.1	-3.3
Margins (%)	21.3	23.6	20.4	22.3	-90bps	-130bps
Adj. PAT	623	1,343	640	1,364	2.8	1.6
EPS	4.7	10.0	4.8	10.2	1.9	2.0

## Consolidated Financials

### Profit & Loss

Y.E March (Rs. Cr)	FY23A	FY24A	FY25A	FY26E	FY27E
<b>Sales</b>	<b>11,174</b>	<b>14,406</b>	<b>15,262</b>	<b>17,938</b>	<b>21,104</b>
% change	36.5	28.9	5.9	17.5	17.6
<b>EBITDA</b>	<b>2,512</b>	<b>2,949</b>	<b>3,166</b>	<b>3,659</b>	<b>4,704</b>
% change	34.2	33.3	27.0	20.0	33.1
Depreciation	1,113	1,569	1,687	1,812	1,978
<b>EBIT</b>	<b>1,399</b>	<b>1,380</b>	<b>1,479</b>	<b>1,847</b>	<b>2,725</b>
Interest	419	974	897	879	862
Other Income	-83	1,120	1,305	230	249
<b>PBT</b>	<b>897</b>	<b>1,525</b>	<b>1,887</b>	<b>1,197</b>	<b>2,112</b>
% change	-8.7	70.0	23.7	-36.6	76.5
Tax	254	227	457	299	528
Tax Rate (%)	28.3	14.9	24.2	25.0	25.0
<b>Reported PAT</b>	<b>643</b>	<b>1,298</b>	<b>1,429</b>	<b>898</b>	<b>1,584</b>
PAT att. to common shareholders	463	1,023	1,013	628	1,364
Adj.*	291	-869	-1,154	12	-
<b>Adj. PAT</b>	<b>754</b>	<b>153</b>	<b>-140</b>	<b>640</b>	<b>1,364</b>
% change	-0.7	-79.7	-191.6	557.1	113.1
No. of shares (cr)	120.1	120.1	120.1	133.7	133.7
<b>Adj EPS (Rs.)</b>	<b>6.3</b>	<b>1.3</b>	<b>-1.2</b>	<b>4.8</b>	<b>10.2</b>
% change	-0.7	-79.4	-192.3	500.0	112.5
DPS (Rs.)	1.5	1.8	1.3	0.8	1.2

### Balance Sheet


Y.E March (Rs. Cr)	FY23A	FY24A	FY25A	FY26E	FY27E
Cash	1,324	1,234	3,227	3,941	4,068
Accts. Receivable	3,573	6,231	5,488	5,561	5,698
Inventories	4,244	4,944	4,931	6,773	7,008
Other Cur. Assets	3,194	2,771	2,640	2,342	2,416
Investments	742	684	680	695	700
Gross Fixed Assets	12,843	14,439	16,120	18,256	20,570
Net Fixed Assets	6,419	8,791	8,800	9,180	10,215
CWIP	3,445	2,613	4,010	4,132	4,137
Intangible Assets	26,662	26,659	27,058	28,330	28,944
Def. Tax -Net	301	317	258	259	262
Other Assets	2,139	1,828	1,706	1,656	1,670
<b>Total Assets</b>	<b>52,043</b>	<b>56,071</b>	<b>58,797</b>	<b>62,868</b>	<b>65,116</b>
Current Liabilities	6,031	12,562	8,984	12,994	14,175
Provisions	227	238	261	276	304
Debt Funds	22,599	17,295	21,123	20,516	20,111
Other Liabilities	698	702	718	578	596
Equity Capital	600	600	600	600	600
Res. & Surplus	17,267	19,183	21,044	21,565	22,772
Shareholder Funds	17,867	19,784	21,644	22,166	23,373
Minority Interest	4,622	5,491	6,069	6,338	6,558
<b>Total Liabilities</b>	<b>52,043</b>	<b>56,071</b>	<b>58,797</b>	<b>62,868</b>	<b>65,116</b>
BVPS	149	165	180	166	175

### Cashflow

Y.E March (Rs. Cr)	FY23A	FY24A	FY25A	FY26E	FY27E
<b>Net inc. + Depn.</b>	<b>1,756</b>	<b>2,867</b>	<b>3,116</b>	<b>2,710</b>	<b>3,562</b>
Non-cash adj.	1,356	455	-184	2,666	913
Other adjustments	-	-	-	-	-
Changes in W.C	-1,259	-367	1,129	452	623
<b>C.F. Operation</b>	<b>1,853</b>	<b>2,954</b>	<b>4,061</b>	<b>5,828</b>	<b>5,098</b>
Capital exp.	-1,723	-1,908	-2,343	-3,587	-3,632
Change in inv.	2,983	1,312	1,992	-35	-39
Other invest.CF	-15,541	-409	117	-	-
<b>C.F - Investment</b>	<b>-14,282</b>	<b>-1,005</b>	<b>-234</b>	<b>-3,621</b>	<b>-3,671</b>
Issue of equity	1,202	31	10	-	-
Issue/repay debt	12,405	-1,313	434	-500	-300
Dividends paid	-72	-203	-83	-107	-157
Other finance.CF	-486	-847	-2,216	-886	-844
<b>C.F - Finance</b>	<b>13,049</b>	<b>-2,333</b>	<b>-1,854</b>	<b>-1,493</b>	<b>-1,301</b>
Chg. in cash	619	-383	1,973	714	126
Closing Cash	1,324	1,234	3,227	3,941	4,068

### Ratio

Y.E March	FY23A	FY24A	FY25A	FY26E	FY27E
<b>Profitab. &amp; Return</b>					
EBITDA margin (%)	22.5	20.5	20.7	20.4	22.3
EBIT margin (%)	12.5	9.6	9.7	10.3	12.9
Net profit mgn. (%)	4.1	7.1	6.6	3.5	6.5
ROE (%)	3.6	6.6	6.6	4.0	6.8
ROCE (%)	3.1	3.2	3.0	3.8	5.4
<b>W.C &amp; Liquidity</b>					
Receivables (days)	116.7	157.9	131.2	113.2	98.6
Inventory (days)	422.9	368.4	346.3	345.2	328.5
Payables (days)	382.8	467.4	459.9	459.9	474.5
Current ratio (x)	1.4	1.0	1.1	1.0	1.0
Quick ratio (x)	0.7	0.5	0.6	0.5	0.5
<b>Turnover &amp; Leverage</b>					
Gross asset T.O (x)	0.9	1.1	1.0	1.0	1.1
Total asset T.O (x)	0.3	0.3	0.3	0.3	0.3
Int. covge. ratio (x)	3.3	1.4	1.6	2.1	3.2
Adj. debt/equity (x)	1.0	0.7	0.8	0.7	0.7
<b>Valuation</b>					
EV/Sales (x)	4.5	3.7	4.3	4.3	3.7
EV/EBITDA (x)	20.2	18.1	20.5	21.3	16.5
P/E (x)	32.9	206.7	n.m.	85.6	40.2
P/BV (x)	1.4	1.6	1.9	2.5	2.3



## Investment Rating Criteria

Ratings	Large caps	Midcaps	Small Caps
Buy	Upside is above 10%	Upside is above 15%	Upside is above 20%
Accumulate	-	Upside is between 10%-15%	Upside is between 10%-20%
Hold	Upside is between 0% - 10%	Upside is between 0%-10%	Upside is between 0%-10%
Reduce/sell	Downside is more than 0%	Downside is more than 0%	Downside is more than 0%
Not rated/Neutral			
<b>Definition:</b>			
<b>Buy:</b> Acquire at Current Market Price (CMP), with the target mentioned in the research note; <b>Accumulate:</b> Partial buying or to accumulate as CMP dips in the future; <b>Hold:</b> Hold the stock with the expected target mentioned in the note.; <b>Reduce:</b> Reduce your exposure to the stock due to limited upside.; <b>Sell:</b> Exit from the stock; <b>Not rated/Neutral:</b> The analyst has no investment opinion on the stock.			
<b>Symbols definition:</b>	 Upgrade	 No Change	 Downgrade

To satisfy regulatory requirements, we attribute 'Accumulate' as Buy and 'Reduce' as Sell.

The recommendations are based on 12 month horizon, unless otherwise specified. The investment ratings are on absolute positive/negative return basis. It is possible that due to volatile price fluctuation in the near to medium term, there could be a temporary mismatch to rating. For reasons of valuations/ return/lack of clarity/event we may revisit rating at appropriate time. Please note that the stock always carries the risk of being upgraded to BUY or downgraded to a HOLD, REDUCE or SELL.

Not rated/Neutral- The analyst has no investment opinion on the stock under review.

## DISCLAIMER & DISCLOSURES

**Certification:** I, Antu Eapan Thomas, author of this Report, hereby certify that all the views expressed in this research report reflect our personal views about any or all of the subject issuer or securities. This report has been prepared by the Research Team of Geojit Investments Limited, hereinafter referred to as GIL.

For general disclosures and disclaimer: Please [Click here](#)

CRISIL has provided research support in preparation of this research report and the investment rational contained herein along with financial forecast. The target price and recommendation provided in the report are strictly GIL's views and are NOT PROVIDED by CRISIL. Further, CRISIL expresses no opinion on valuation and the associated recommendations. CRISIL has no financial liability whatsoever, to the subscribers / users of this report.

### Regulatory Disclosures:

Group companies/ Fellow subsidiaries of Geojit Investments Ltd (GIL ) are Geojit Financial Services Limited (GFSL), Geojit Technologies Private Limited (Software Solutions provider), Geojit Credits Private Limited (NBFC), Geojit Fintech Private Ltd, Geojit IFSC Ltd (a company incorporated under IFSC Regulations), Qurum Business Group Geojit Securities LLC ( a subsidiary of holding company in Oman engaged in Financial Services ), Barjeel Geojit Financial Services LLC (a joint venture of holding company in UAE engaged in Financial Services), and BBK Geojit Consultancy and Information KSC (C) (a joint venture in Kuwait-engaged in Financial services). In the context of the SEBI Regulations on Research Analysts (2014), GIL affirms that we are a SEBI registered Research Entity and in the course of our business as a stock market intermediary, we issue research reports /research analysis etc. that are prepared by our Research Analysts. We also affirm and undertake that no disciplinary action has been taken against us or our Analysts in connection with our business activities.

In compliance with the above-mentioned SEBI Regulations, the following additional disclosures are also provided which may be considered by the reader before making an investment decision:

#### 1. Disclosures regarding Ownership:

GIL confirms that:

(i)It/its associates have no financial interest or any other material conflict in relation to the subject company (ies) covered herein, at the time of publication of the research report.  
 (ii)It/its associates have no actual beneficial ownership of 1% or more in relation to the subject company (ies) covered herein, at the end of the month immediately preceding the date of publication of the research report.

Further, the Analyst confirms that:

(i) He/his associates/his relatives have no other financial interest in the subject company other than holding shares in very small quantity in the subject company at the time of publication of the research report.  
 (ii) He, his associates and his relatives have no actual/beneficial ownership of 1% or more in the subject company covered, at the end of the month immediately preceding the date of publication of the research report.

#### 2. Disclosures regarding Compensation:

During the past 12 months, GIL or its Associates:

(a) Have not received any compensation from the subject company; (b) Have not managed or co-managed public offering of securities for the subject company (c) Have not received any compensation for investment banking or merchant banking or brokerage services from the subject company. (d) Have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company. e) Have not received any compensation or other benefits from the subject company or third party in connection with the research report (f) The subject company is / was not a client during twelve months preceding the date of distribution of the research report.

#### 3. Disclosure by GIL regarding the compensation paid to its Research Analyst:

GIL hereby confirms that no part of the compensation paid to the persons employed by it as Research Analysts is based on any specific brokerage services or transactions pertaining to trading in securities of companies contained in the Research Reports.

4. Disclosure regarding the Research Analyst's connection with the subject company: It is affirmed that I, Antu Eapan Thomas, Research Analyst (s) of GIL have not served as an officer, director or employee of the subject company.

5. Disclosure regarding Market Making activity: Neither GIL/its Analysts have engaged in market making activities for the subject company.

6. Disclosure regarding conflict of interests: GIL shall abide by the applicable regulations/ circulars/ directions specified by SEBI and Research Analyst Administration and Supervisory Body (RAASB) from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. GIL will endeavour to promptly inform the client of any conflict of interest that may affect the services being rendered to the client.

7. "Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."

8. Clients are required to keep contact details, including email id and mobile number/s updated with the GIL at all times.

9. In the course of providing research services by GIL, GIL cannot execute/carry out any trade (purchase/sell transaction) on behalf of, the client. Thus, the clients are advised not to permit GIL to execute any trade on their behalf.

10. GIL will never ask for the client's login credentials and OTPs for the client's Trading Account Demat Account and Bank Account. The Clients are advised not to share such information with anyone including GIL.

**11. Standard Warning:** "Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

12. Disclosures regarding Artificial Intelligence tools: Neither Geojit Investments Limited nor its Analysts have utilized any AI tools in the preparation of the research reports.

Please ensure that you have read the "Risk Disclosure Documents for Capital Market and Derivatives Segments" as prescribed by the Securities and Exchange Board of India before investing.

**Geojit Investments Ltd.** Registered Office: 7th Floor 34/659-P, Civil Line Road, Padivattom, Kochi-682024, Kerala, India. Phone: +91 484-2901000, Website : [www.geojit.com/GIL](http://www.geojit.com/GIL) . For investor queries: [customerservice@geojit.com](mailto:customerservice@geojit.com)

### GRIEVANCES

**Step 1:** The client should first contact the RA using the details on its website or following

contact details: Compliance officer: Ms. Indu K. Address: 7th Floor, 34/659-P, Civil Line Road, Padivattom, Ernakulam,; Phone: +91 484-2901367; Email: [compliance@geojit.com](mailto:compliance@geojit.com). For Grievances: [grievances@geojit.com](mailto:grievances@geojit.com). **Step 2:** If the resolution is unsatisfactory, the client can also lodge grievances through SEBI's SCORES platform at [www.scores.sebi.gov.in](http://www.scores.sebi.gov.in) **Step 3:** The client may also consider the Online Dispute Resolution (ODR) through the Smart ODR portal at <https://smartodr.in>

Corporate Identity Number: U66110KL2023PLC080586, Research Entity SEBI Reg No: INH000019567; Depository Participant : IN-DP-781-2024.